0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

ARGYRIA RESULTING FROM INTRANASAL MEDICATION:  A CLINICAL AND EXPERIMENTAL STUDY

BEN L. BRYANT, M.D.
Arch Otolaryngol. 1940;31(1):127-139. doi:10.1001/archotol.1940.00660010128013.
Text Size: A A A
Published online

Despite the warnings that have appeared occasionally in the literature, many otolaryngologists still deny the danger of the production of generalized argyria from the use of silver-containing intranasal medication. This heedless attitude is abetted by the advertisements of certain manufacturers of such medications. One of them states quite consistently in the advertising pages of medical publications that the solution is "non-toxic, definitely bacteriostatic, and above all, it is markedly soothing to inflamed tissues."

The physician who has seen even a single victim of full-blown argyrosis, with its typical generalized pigmentation of the skin, giving the patient a bronzed blue or slate color which has been described aptly as the appearance of a corpse suddenly come to life, must necessarily have been impressed with the importance of preventing such a condition. Prevention is actually the only treatment, for, although Stillians1 and others have shown that by painstaking and multitudinous injections of

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();